Young left the FDA in 1989 to become Deputy Assistant Secretary for Health, Science, and Environment under Health and Human Services Secretary
Louis Wade Sullivan. Subsequently, Young served as director of both the Office of Emergency Preparedness and the National Disaster Medical System during the Clinton Administration, from 1993 until his retirement from federal service in 1996. In 2013, Young joined Braeburn Pharmaceuticals as executive vice president, clinical and regulatory affairs to contribute to the development of the
new drug application (NDA) to FDA for evaluation of Braeburn’s Probuphine (
buprenorphine) implant, which was approved on May 26, 2016. Probuphine is the first buprenorphine implant for the maintenance treatment of opioid dependence. Young has advised numerous pharmaceutical companies on regulatory issues and clinical development. He served as interim vice president for clinical and regulatory affairs of Bioventus Global and became an adjunct partner and partner at Essex Woodlands in 2002. He also co-founded the Cosmos Alliance and served as its chairman and chief executive officer. He served as the executive vice president of clinical and regulatory affairs at TissueTech Inc, where he was tasked to lead the company in its transition from a HCT/P regulated company into a biologics company through the pursuit of multiple NDAs for ultimate
BLA approval. ==Awards and achievements==